β-endorphin and cholecystokinin 8 concentrations in peripheral blood mononuclear cells of autistic children

Neuropsychobiology

Volumn 35, Issue 1, 1997, Pages 1-4

  Brambilla, F ^a   Guareschi Cazzullo, A G ^b   Tacchini, C ^b   Musetti, C ^b   Panerai, A E ^a   Sacerdote, P ^c  

^a Ospedale Psichiatrico Pini   (Italy)

^b Istituto Neuropsichiatria Infantile e   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Autism; Cholecystokinin 8; Peripheral blood mononuclear cells; Pervasive developmental disorders; Endorphin

Indexed keywords

BETA ENDORPHIN; CHOLECYSTOKININ OCTAPEPTIDE;

ARTICLE; CELL LEVEL; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; FEMALE; HUMAN; HUMAN CELL; INFANT; INFANTILE AUTISM; MALE; MONONUCLEAR CELL; NERVE CELL; PRIORITY JOURNAL; PROTEIN SECRETION;

ADOLESCENT; AUTISTIC DISORDER; BETA-ENDORPHIN; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MONOCYTES; REFERENCE VALUES; SINCALIDE;

EID: 0031036544     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119322     Document Type: Article

References (43)

1. Panksepp J: A neurochemical theory of autism. Trends Neurosci 1979:2:174-177.
2. Panksepp J, Sahley T: Possible brain opioid involvement in disrupted social intent and language development of autism; in Schopler E, Mesibow G (eds): Netirobiological Issues in Autism. New York. Plenum Press, 1987.
3. Kalat JM: Speculations on similarities between autism and opiate addiction. J Autism Child Schizophr 1978;8:477-479.
4. Sandyk R, Gillman MA: Infantile autism: A dysfunction of the opioids? Med Hypotheses 1986;19:41-45.
5. Deutsch SI: Rationale for the administration of opiate antagonists in treating infantile autism. Am J Ment Defic 1986;90:631-635.
6. Sahley TL, Panksepp J: Brain opioids and autism: An update analysis of possible linkages. J Autism Dev Dis 1987;17:201-216.
7. Chamberlain RS, Herman BH: A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides and serotonin in autism. Biol Psychiatry 1990:28: 773-779.
8. Herman B, Hammock K, Arthur-Smith A, Egan J, Chatoor I, Werner A, Zelnik N: Naltrexone decreases self-injurious behavior. Ann Neurol 1987;22:550-552.
9. Herman B: Effects of opioid receptor antagonists in the treatment of autism and self-injurious behavior; in Ratey JJ (ed): Mental retardation: Developing pharmacotherapies. Progress in Psychiatry. Washington. American Psychiatric Press, 1991.
10. Campbell M, Adams P, Small AM, McVeigh Tesch L, Curren EL: Naltrexone in infantile autism. Psychopharmacol Bull 1988:24:135-139.
11. Campbell M, Overall JE, Small AM, Sokol M, Spencer E, Adams P, Foltz R. Monti K, Nobler M, Roberts E: Naltrexonne in autistic children: An acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 1989:28:200-206.
12. Campbell M, Anderson LT, Small AM. Loca-scio JJ, Lynch NS, Choroco MC: Naltrexone in autistic children: A double-blind and placebo-controlled study. Psychopharmacol Bull 1990: 26:130-135.
13. Campbell M, Anderson IT, Small AM, Adams P, Gonzales NM, Ernst M: Naltrexone in autistic children: Behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993:32:1283-1291.
14. Leboyer M, Bouvard M, Dugas M: Effects of naltrexone in infantile autism. Lancet 1988;i: 8687-8715.
15. Leboyer M, Bouvard MP, Launay JM, Tabuteau F, Waller D, Dugas M, Kerdelhue B, Lensing P, Panksepp J: Brief report: A double-blind study of naltrexone in infantile autism. J Autism Dev Disord 1992;22:309-319.
16. Panksepp J, Lensing P: Naltrexone treatment of autism: A synopsis of an open trial with four children. J Autism Dev Disord 1991:21:135-141.
17. Walters AS, Barrett RP, Feinstein C, Mercurio A, Hole WT: A case report of naltrexone treatment of self-injury and social withdrawal in autism. J Autism Dev Disord 1990:20:169-176.
18. Gillberg C, Tercnius L, Lonncrholm G: Endorphin activity in childhood psychosis: Spinal fluid levels in 24 cases. Arch Gen Psychiatry 1985;42:780-783.
19. Ross DL, Klykylo WM, Hitzemann R: Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. Pediatr Neurol 1987;3:83-86.
20. Weizman R, Weizman A, Tyano S, Szekcly G, Weissman BA. Same Y: Humoral endorphin blood levels in autistic, schizophrenic and healthy subjects. Psychopharmacology 1984; 82:368-370.
21. Weizman R, Gil-Ad I, Dick J, Szekcly GA, Laron Z: Low plasma immunoreactivity beta-endorphin levels in autism. J Am Acad Child Adolesc Psychiatry 1988;27:430-433.
22. Ernst M, Devi L, Silva RR, Gonzales NM, Small AM, Malone RP, Campbell M: Plasma beta-endorphin levels, naltrexone and haloperidol in autistic children. Psychopharmacol Bull 1993;29:221-227.
23. Marchetti B, Scifo R, Batticane N, Scapagnini U: Immunological significance of opioid dysfunction in infantile autism. Brain Dysfunet 1990:3:346-354.
24. Sandman CA, Barron JL, Chicz-DeMet A, De-Mel EM: Brief report: Plasma p-endorphin and cortisol levels in autistic patients. J Autism Dev Disord 1991:21:83-87.
25. Lcboyer M, Bouvard MP, Recasens C, Philippe A, Guilloud-Bataille M, Bondoux D, Tabuteau F, Dugas M, Panksepp J, Launay JM: Difference between plasma N- and C-terminally directed p-endorphin immunoreactivity in infantile autism. Am J Psychiatry 1994:151:1797-1801.
26. Kavelaars A, Ballieux RE, Heijnen CJ: β-Endorphin secretion by human peripheral blood mononuclear cells: Regulation by glucocorticoids. Life Sci 1990;46:1233-1240.
27. Sacerdote P, Rubboli F, Locatelli L, Ciciliato I, Mantegazza P, Panerai AE: Pharmacological modulation of neuropeptides in peripheral mononuclear cells. J Neuroimmunol 1991;32: 35-41.
28. Panza G, Monzani E, Sacerdote P, Penati G, Panerai AE: Beta-endorphin, vasoactive intestinal peptide and cholecystokinin in peripheral blood mononuclear cells from healthy subjects and schizophrenic patients. Acta Psychiatr Scand 1991;82:207-210.
29. Young JG, Kavanagh ME, Anderson GM. Shaywitz BA, Cohen DJ: Clinical ncurochentis-try of autism and associated disorders. J Autism Dev Disord 1982:12:147-165.
30. Meyer DK, Krauss J: Dopamine modulates cholecystokinin release in neostriatum. Nature 1983;301:338-340.
31. Gillberg C, Svennerholm L, Hamilton-Hell-berg C: Childhood psychosis and monoamine metabolites in spinal fluid. J Autism Dev Disord 1983;13:383-396.
32. Gamier C, Contoy E, Barthelemy C, Leddet I, Garreau B, Muh JP, Lelord G: Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children. J Autism Dev Disord 1986;16:23-29.
33. Martin JR, Beinfeld MC, Wang RY: Modulation of cholecystokinin release from posterior nucleus accumbens by D-2 dopamine receptor. Brain Res 1986:397:253-258.
34. Launay JM, Bursztein C, Ferrari P, Dreux C, Braconnier A, Zariftan E, Lancrenon S, Ferntanian J: Catecholamine metabolism in infantile 22 autism: A controlled study of 22 autistic children. J Autism Dev Disord 1987; 17:333-347.
35. Martincau J, Barthelemy C, Jouve J, Muth JP, Lelord G: Monoamines (serotonin and catecholamines) and their derivatives in infantile autism: Age-related changes and drug effects. Dev Med Child Neurol 1992:34:593-603.
36. American Psychiatric Association: DSM III-R: Diagnostic and Statistical Manual of Mental Disorders, ed III rev. Washington. American Psychiatric Press, 1987.
37. The ICD-10 classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva. World Health Organization. 1992.
38. Le Couteur A, Rutter A, Lord C, Rios P, Robertson S, Holdgrafer M, McLennan G: Autism diagnostic interview: A standardized investigator-based instrument. J Autism Dev Disord 1984;19:363-388.
39. Lord C, Rutter A: Autism diagnostic observation schedule. J Autism Dev Disord 1989:19: 185-212.
40. Panerai AE, Pardi G, Martini A, Di Giulio AM, Fraioli F, Vegni G, Martini A, Mantegazza P: Plasma β-endorphin, β-lipotropin and metenkephalin concentrations during pregnancy in normal and drug-addicted women with their newborn. J Clin Endocrinol Metab 1983; 57:537-543.
41. Sacerdote P, Wiederman CJ, Wahl LM, Pert CB, Ruff MR: Visualization of cholecystokinin receptors on a subset of human monocytes and in rat spleen. Peptides 1991:12:167-176.
42. Barthelemy C, Adrien JL, Tanguay P, Garreau B, Fermanian J, Roux S, Sauvage D. Lelord G: The behavioral summarized evaluation: Validity and reliability of a scale for the assessment of autistic behavior. J Autism Dev Disord 1990;20:189-203.
43. Frederikson RCA, Geary LE: Endogenous opioid peptides: Review of psychological, pharmacological and clinical aspects. Prog Neurobiol 1982;19:19-69.